Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Disease save search
VitaGraft Kidney Expands Utility in Recurrent Primary Disease Patients
Published: 2023-07-25 (Crawled : 13:00) - globenewswire.com
OCX | News J | $2.495 -2.54% -2.61% 50K
|
Health Technology
|
| O: 2012.46%
H: 0.0%
C: 0.0%
disease kidney
Jasper Therapeutics Announces Positive Clinical Data from a Phase I/II Trial of Briquilimab as a Conditioning Treatment in Sickle Cell Disease and Beta Thalassemia
Published: 2023-01-03 (Crawled : 14:00) - biospace.com/
JSPR | $21.61 -6.89% -7.4% 65K
|
|
| O: 210.62%
H: 153.33%
C: 82.67%
treatment disease trial therapeutics positive
Cardio Diagnostics Holdings Inc Launches Revolutionary Blood Test for Early Detection of Coronary Heart Disease
Published: 2023-02-28 (Crawled : 16:00) - biospace.com/
CDIO 4 | $0.875 -19.73% -24.57% 700K
|
|
| O: 183.19%
H: 5.82%
C: -8.73%
blood disease test heart cardio diagnostics
IGC Announces Issuance of Patent for the Treatment of Alzheimer’s Disease Using THC
Published: 2021-07-22 (Crawled : 16:00) - igcinc.us
IGC 4 | $0.49 2.92% 0.74% 610K
|
Health Technology
|
| O: 165.54%
H: 18.32%
C: -28.75%
disease alzheimer treatment patent alzheimer’s alzheimer's disease alzheimer's
Alterity Therapeutics Reports Positive Efficacy Data for ATH434 in a Primate Model of Parkinson’s Disease
Published: 2023-12-03 (Crawled : 00:00) - alteritytherapeutics.com
ATHE | $2.04 -4.67% -4.9% 54K
|
Health Technology
|
| O: 156.02%
H: 27.29%
C: -1.18%
ath434 disease positive parkinson’s therapeutics
Alterity Therapeutics Reports Positive Efficacy Data for ATH434 in a Primate Model of Parkinson’s Disease
Published: 2023-12-04 (Crawled : 12:30) - globenewswire.com
ATHE | $2.04 -4.67% -4.9% 54K
|
Health Technology
|
| O: 156.02%
H: 27.29%
C: -1.18%
ath434 disease positive parkinson’s therapeutics
BioVie’s NE3107 Demonstrates Potential Improvements in Motor and Non-motor Symptoms for Parkinson’s Disease Patients and May Be Realigning Physiological Processes for Alzheimer’s Patients in Data to be Presented at the International Conference on Alzheimer’s and Parkinson’s Diseases 2024
Published: 2024-03-01 (Crawled : 13:00) - globenewswire.com
BIVI | $0.4874 -0.21% -0.21% 490K
|
Health Technology
|
| O: 141.13%
H: 10.7%
C: -36.79%
ne3107 conference disease alzheimer’s international parkinson’s potential
HeartSciences Granted Key Israeli International Patent for its MyoVista® Wavelet Technology Utilizing Artificial Intelligence (AI) for Early Detection of Heart Disease
Published: 2023-02-06 (Crawled : 15:00) - biospace.com/
HSCS | $0.101 -6.91% -7.43% 1.1M
|
n/a
|
| O: 106.34%
H: 5.46%
C: -4.44%
myovista patent disease heart technology granted international
U.S. Food and Drug Administration Approves Immix Biopharma Rare Pediatric Disease Designation for IMX-110 as a Treatment for Life-Threatening Pediatric Cancer in Children
Published: 2022-01-03 (Crawled : 14:30) - biospace.com/
IMMX | $2.21 0.0% 64K
|
|
| O: 98.03%
H: 23.12%
C: -18.01%
imx-110 treatment biopharma drug disease food rare pediatric disease designation cancer children designation rare
Ipsen to Acquire Albireo Accelerating Growth in Rare Disease With Treatments for Several Pediatric Liver Diseases
Published: 2023-01-09 (Crawled : 11:00) - biospace.com/
ALBO | $44.15 -0.23% 0.39% 1.2M
|
Health Technology
|
| O: 91.65%
H: 0.0%
C: 0.0%
rare liver acquire disease growth
Hoth Therapeutics Announces Positive Preclinical Results of HT-ALZ treatment for Alzheimer's Disease
Published: 2023-06-06 (Crawled : 15:00) - biospace.com/
HOTH | $1.22 3.39% 3.28% 22K
|
Health Technology
|
| O: 88.3%
H: 21.47%
C: -5.37%
disease positive treatment preclinical alzheimer's therapeutics ht-alz results
Palisade Bio Transforms GI-Focused Pipeline Through Exclusive Worldwide Licensing Agreement with Giiant Pharma, Inc. for Multiple Oral Drug Candidates Targeting Inflammatory Bowel Disease
Published: 2023-09-06 (Crawled : 13:00) - globenewswire.com
PALI | $4.735 -6.61% -7.07% 140K
|
Manufacturing
|
| O: 79.79%
H: 55.65%
C: 16.13%
drug disease worldwide pipeline agreement
Genetic Technologies Provides Update on its COVID-19 Disease Severity Risk Test and Expansion into Germline Testing
Published: 2021-01-21 (Crawled : 12:01) - globenewswire.com
GENE 1 d | $2.27 -6.97% -7.49% 64K
|
Health Technology
|
| O: 76.74%
H: 7.63%
C: -27.89%
covid test disease risk expansion
Acumen Pharmaceuticals to Hold Conference Call to Discuss Positive Topline Results from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer’s Disease
Published: 2023-07-17 (Crawled : 11:00) - globenewswire.com
ABOS | $3.14 -0.63% -0.64% 310K
|
Professional, Scientific, and T...
|
| O: 75.32%
H: 2.72%
C: -11.72%
acu193 conference disease alzheimer’s positive pharmaceuticals topline results study
AC Immune Announces First Positive Cognitive Results for a Tau-Targeting Monoclonal Antibody in Alzheimer’s Disease
Published: 2021-08-31 (Crawled : 12:00) - globenewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.2%
H: 0.3%
C: -1.73%
ACIU | $2.375 -0.21% -0.21% 320K
|
Health Technology
|
| O: 71.82%
H: 5.0%
C: -32.31%
disease alzheimer positive results antibody semorinemab alzheimer’s alzheimer's disease alzheimer's
Vaxcyte to Host Webcast and Conference Call to Discuss Topline Results from the Phase 1/2 Proof-of-Concept Study of VAX-24 Being Investigated for the Prevention of Invasive Pneumococcal Disease in Adults
Published: 2022-10-23 (Crawled : 00:00) - globenewswire.com
PCVX | $60.82 0.33% 0.33% 1.3M
|
Health Technology
|
| O: 70.8%
H: 2.7%
C: -6.12%
STRO | $3.635 -3.58% -3.71% 520K
|
Health Technology
|
| O: 0.71%
H: 14.96%
C: 13.91%
vax-24 conference disease topline study pneumococcal
Vaxcyte Reports Positive Topline Data from Phase 1/2 Proof-of-Concept Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Pneumococcal Disease in Adults Aged 18-64
Published: 2022-10-24 (Crawled : 11:00) - biospace.com/
PPRUF | $358.55 37.56% 1.5K
|
Consumer Non-Durables
|
| O: 0.55%
H: 3.41%
C: -0.9%
PPRUY | $36.0023 -0.11% 220K
|
Manufacturing
|
| O: -0.01%
H: 0.83%
C: -0.01%
PCVX | $60.82 0.33% 0.33% 1.3M
|
Health Technology
|
| O: 70.8%
H: 2.7%
C: -6.12%
STRO | $3.635 -3.58% -3.71% 520K
|
Health Technology
|
| O: 0.71%
H: 14.96%
C: 13.91%
candidate disease topline vaccine positive study pneumococcal
Zevra Therapeutics to Acquire Acer Therapeutics, Expanding its Rare Disease Portfolio and Adding Commercial Product
Published: 2023-08-31 (Crawled : 12:00) - globenewswire.com
ZVRA | $4.515 0.33% 0.33% 360K
|
n/a
|
| O: 0.0%
H: 0.0%
C: -4.34%
ACER | $0.9 -3.61% 420K
|
Health Technology
|
| O: 70.49%
H: 0.0%
C: 0.0%
rare disease acquire commercial therapeutics
Regulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Published: 2024-03-12 (Crawled : 12:30) - biospace.com/
RGLS | $2.13 -4.05% -4.23% 220K
|
Health Technology
|
| O: 68.84%
H: 62.66%
C: 1.29%
rgls8429 disease kidney positive treatment topline trial therapeutics
Hoth Therapeutics Announces HT-ALZ Therapeutic Shows Positive Results - Reduce Amyloid β in Alzheimer's Disease
Published: 2022-01-04 (Crawled : 13:00) - ir.hoththerapeutics.com
HOTH | $1.22 3.39% 3.28% 22K
|
Health Technology
|
| O: 61.79%
H: 53.51%
C: 14.04%
alzheimer therapeutics disease positive results positive results alzheimer’s alzheimer's disease alzheimer's ht-alz
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.